Brofaromine (CGP 11 305 A): estimation of plasma concentrations by a biologic technique as compared to liquid chromatography.
In an open clinical trial 13 depressives significantly improved under the reversible and selective type-A monoamine oxidase (MAO) inhibitor brofaromine. The inhibitory potency of deproteinated plasma on a crude MAO preparation from human placenta was measured as a parameter for plasma brofaromine. There were no significant differences in plasma MAO inhibitory potency between responders (improvement greater than 50%; n = 5) and non-responders. MAO inhibitory potency significantly (p less than 0.05) increased parallel to the increase of the dosage from 50 mg b.i.d. to t.i.d. confirming the validity of this technique. The biologic assay, however, overestimated brofaromine by a factor of two in acute kinetic experiments with healthy volunteers as compared to a chromatographic technique, although both methods significantly correlated (r = 0.928).
Fritze
J
J
Department of Psychiatry and Clinical Neurochemistry, School of Medicine, University of Würzburg, Federal Republic of Germany.
Becker
T
T
Ziegler
V
V
Laux
G
G
Bieck
P
P
Sofic
E
E
Riederer
P
P
D000328:Adult; D000368:Aged; D002853:Chromatography, Liquid; D003866:Depressive Disorder / Q000188:drug therapy; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D008928:Mitochondria / Q000201:enzymology; D008996:Monoamine Oxidase Inhibitors / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D010880:Piperidines / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D010920:Placenta / Q000201:enzymology; D011247:Pregnancy
D008996:Monoamine Oxidase Inhibitors; D010880:Piperidines; C038213:brofaromine